Fixed-Duration and De-escalated Therapy

Doing less on purpose: fixed-duration regimens tested against treatment until progression, risk-adapted observation, and the evidence needed before an established therapy can safely be shortened or withheld.

7 articles in this topic

• July 24, 2026Annals of OncologyNCT01272037

  Low Ovarian Reserve Predicts No Chemotherapy Benefit in Node-Positive, HR-Positive Breast Cancer

  A prespecified biomarker analysis of the phase 3 RxPONDER (SWOG S1007) trial finds that serum anti-Müllerian hormone (AMH), a marker of ovarian reserve, identifies which women under 55 with hormone receptor-positive, HER2-negative, node-positive breast cancer actually benefit from adding chemotherapy to endocrine therapy — outperforming menopausal status and age as a predictor.

• May 28, 2026Annals of OncologyNCT02308085

  Pregnancy After Interrupting Endocrine Therapy Shows No Excess Breast Cancer Risk at 6 Years

  Updated results from the prospective, single-arm POSITIVE trial — now with a median follow-up of 71 months, up from 41 months at the original analysis — found no increase in breast cancer recurrence risk among young women with hormone receptor-positive disease who paused adjuvant endocrine therapy to attempt pregnancy.

• August 20, 2026JAMA Oncology

  Meningioma Diagnoses Nearly Doubled in Denmark Over 14 Years — But Most Surveillance Scans Never Led to Treatment

  A nationwide Danish registry study of 8,134 patients found that age- and sex-standardized meningioma incidence nearly doubled between 2010 and 2023, rising from 6.4 to 12.6 cases per 100,000 person-years, while the proportion of diagnosed patients who ultimately received surgery fell from 43.9% to 23.4%.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

• August 10, 2026Journal of Clinical OncologyNRG Oncology RTOG 0539 (NCT00895622)

  10-Year Data Validate Risk-Adapted Meningioma Strategy: Observation, Then Selective Radiotherapy

  Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.

• July 16, 2026New England Journal of MedicineENDURANCE (ECOG-ACRIN E1A11) maintenance randomization (NCT01863550)

  Indefinite Lenalidomide Maintenance Fails to Beat 2-Year Fixed Duration in Myeloma

  Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.

• March 12, 2026New England Journal of MedicineCLL17 (NCT04608318)

  Fixed-Duration Therapy Matches Continuous Treatment in Previously Untreated Chronic Lymphocytic Leukemia: The CLL17 Trial

  Phase 3 randomized trial of 909 patients with previously untreated CLL across 174 sites in 13 countries